In:
Military Medical and Pharmaceutical Journal of Serbia, National Library of Serbia, , No. 00 ( 2023), p. 21-21
Abstract:
Background/Aim. Diclofenac, a non-selective inhibitor of cyclooxygenase, with
analgesic, anti-inflammatory and antipyretic effects, is one of the most
prescribed nonsteroidal anti-inflammatory drugs (NSAIDs). The aim of the
study was to analyse prescribing patterns of diclofenac systemic
formulations at the outpatient care settings (OCS) in Montenegro, in
patients with cardiovascular (CV) disease (CVD) and patients with risk
factors for CVD, during the period 2016-2020. Methods. The retrospective,
national, drug utilisation study, included patients with CVD, to whom
prescribing of diclofenac is contraindicated and patients with risk factors
for CVD, for which diclofenac can be prescribed, but with increased
precaution. Primary health care information system (PHCIS) has been used as
source of medical data for these patients. Results. Within the observed
period, prescribing and consumption of diclofenac systemic formulations,
dominantly oral formulations in 75 mg dose, increased by 36.9 % (from 4.6 of
defined daily doses (DDD) /1,000 inhabitants/day in 2016 to 6.3 DDD/1,000
inhabitants/day in 2020). The rising trend in prescribing diclofenac was
also noted in patients with CVD/ risk factors for CVD, for which diclofenac
prescribing is contraindicated/precautioned. Out of the overall number of
patients who were prescribed diclofenac in 2016, 2017, 2018, 2019 and 2020,
16%, 18%, 24%, 15% and 20% of them, respectively, had a CVD/ risk factor for
CVD. The highest number of CV patients (39.7%), who were contraindicated for
prescribing of diclofenac, had ischemic heart disease (they had been
prescribed 40.7% DDD/1,000 inhabitants/day of diclofenac of overall
prescribed medicine for this group of patients). The highest number (77.4%)
of patients who could be prescribed the drug, but with increased
precautions, had hypertension and they were prescribed in 77.2% of DDD/1,000
inhabitants/day of diclofenac of overall prescribed drug for this group of
patients. Conclusion. Despite undertaken regulatory measures aimed at safer
prescription of diclofenac to patients with CVD or risk factors for CVD,
this medicine is still widely prescribed, even in cases representing
contraindications for its use.
Type of Medium:
Online Resource
ISSN:
0042-8450
,
2406-0720
DOI:
10.2298/VSP221229021S
Language:
English
Publisher:
National Library of Serbia
Publication Date:
2023
detail.hit.zdb_id:
2169819-3
SSG:
15,3
Permalink